Aktuelle Urologie, Table of Contents Aktuelle Urol 2023; 54(04): 269-270DOI: 10.1055/a-2084-8214 Referiert und kommentiert Kommentar zu Kastrationsresistentes Prostatakarzinom: [177Lu]Lu-PSMA-617 versus Cabazitaxel Contributor(s): Tilman Todenhöfer 1 Studienpraxis Urology, Nürtingen, Deutschland 2 Medical School, Universität Tübingen, Tübingen, Deutschland › Author Affiliations Recommend Article Abstract Buy Article Comment on: Kastrationsresistentes Prostatakarzinom: [177Lu]Lu-PSMA-617 versus CabazitaxelAktuelle Urol 2023; 54(04): 269-269DOI: 10.1055/a-2017-7363 Full Text References Literatur 1 Hofman MS, Emmett L, Sandhu S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021; 397: 797-804 2 Hofman MS, Emmett L, Sandhu S. et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel – Overall survival after median follow-up of 3 years (ANZUP 1603). Journal of Clinical Oncology 2022; 40 (Suppl. 16) 5000-5000 3 Buteau JP, Martin AJ, Emmett L. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022; 23: 1389-1397 4 Kuo P, Hesterman J, Rahbar K. et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 5002-5002
